Czech National Bank Acquires 2,489 Shares of Cencora, Inc. (NYSE:COR)

Czech National Bank boosted its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 7.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 38,025 shares of the company's stock after buying an additional 2,489 shares during the period. Czech National Bank's holdings in Cencora were worth $8,543,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Concord Wealth Partners bought a new stake in Cencora in the third quarter valued at $30,000. SYSTM Wealth Solutions LLC acquired a new stake in shares of Cencora in the 2nd quarter valued at $36,000. Ashton Thomas Securities LLC bought a new stake in shares of Cencora in the 3rd quarter worth about $41,000. Fairscale Capital LLC acquired a new stake in shares of Cencora during the 2nd quarter worth about $54,000. Finally, Modus Advisors LLC bought a new position in Cencora during the 4th quarter valued at about $54,000. Institutional investors own 97.52% of the company's stock.

Insiders Place Their Bets

In related news, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now owns 326,557 shares of the company's stock, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the business's stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $228.72, for a total transaction of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 94,696 shares of company stock valued at $22,862,734. Company insiders own 15.80% of the company's stock.

Analyst Upgrades and Downgrades

COR has been the topic of several research analyst reports. UBS Group upped their price objective on shares of Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research note on Thursday, November 7th. Bank of America reaffirmed a "neutral" rating and set a $245.00 price target (down from $275.00) on shares of Cencora in a report on Wednesday, September 18th. Mizuho assumed coverage on Cencora in a research report on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective for the company. Evercore ISI increased their target price on Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Finally, Leerink Partners cut their price target on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a report on Monday, October 7th. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and an average price target of $275.60.

Cencora Trading Down 1.0 %

Shares of NYSE COR traded down $2.31 during mid-day trading on Wednesday, hitting $237.74. The company's stock had a trading volume of 1,186,513 shares, compared to its average volume of 1,303,101. Cencora, Inc. has a one year low of $214.77 and a one year high of $253.27. The company's fifty day simple moving average is $237.95 and its 200-day simple moving average is $233.65. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The stock has a market cap of $45.95 billion, a price-to-earnings ratio of 31.66, a price-to-earnings-growth ratio of 1.54 and a beta of 0.49.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were paid a $0.55 dividend. The ex-dividend date was Friday, November 15th. This is a boost from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a yield of 0.93%. Cencora's dividend payout ratio (DPR) is presently 29.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.